Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
AZD8055
Cat No.
CEI-0118
Description
AZD8055 can inhibit mTOR with IC50 of 0.8 nM.
CAS No.
1009298-09-2
Molecular Weight
465.54
Purity
>99%
Storage
2 years at -20centigrade Powder
Targets
mTOR
Molecular Formula
C25H31N5O4
Chemical Name
(5-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol
Solubility
DMSO 93 mg/mL Water 2 mg/mL Ethanol 15 mg/mL
In vitro
As a ATP-competitive inhibitor, AZD8055 can inihibit mTOR kinase with IC50 of 0.8 nM. AZD8055 shows inhibition to the phosphorylation of p70S6K and 4E-BP1, both of which are mTORC1 substrates. AZD8055 also can inhibit phosphorylation of the mTORC2 substrate AKT and downstream proteins. AZD8055 shows excellent selectivity (approximately 1,000-fold) against all class I phosphatidylinositol 3-kinase (PI3K) isoforms and other members of the PI3K-like kinase family. In vitro, AZD8055 potently inhibits proliferation and induces autophagy in H838 and A549 cells.AZD8055 induces a dose-dependent pharmacodynamic effect on phosphorylated S6 and phosphorylated AKT at plasma concentrations leading to tumor growth inhibition.
In vivo
In mice bearing U87-MG (PTEN null) glioblastoma xenografts, oral treatment with AZD8055 resulted in a dose-dependent tumor growth inhibition of 33%, 48%, and 77% with 2.5, 5, and 10 mg/kg/d twice daily, respectively. Antitumor activity in vivo induced by AZD8055 administered orally at a dose of 10 mg/kg twice daily or 20 mg/kg daily.
Download
Download Datasheet